



# Changes in Automated Mammographic Breast Density Can Predict Pathological Response After Neoadjuvant Chemotherapy in Breast Cancer

Jee Hyun Ahn<sup>1</sup>, Jieon Go<sup>1</sup>, Suk Jun Lee<sup>1</sup>, Jee Ye Kim<sup>1</sup>, Hyung Seok Park<sup>1</sup>, Seung Il Kim<sup>1</sup>, Byeong-Woo Park<sup>1</sup>, Vivian Youngjean Park<sup>2</sup>, Jung Hyun Yoon<sup>2</sup>, Min Jung Kim<sup>2</sup>, Seho Park<sup>1</sup>

<sup>1</sup>Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea

<sup>2</sup>Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea

**Objective:** Mammographic density is an independent risk factor for breast cancer that can change after neoadjuvant chemotherapy (NCT). This study aimed to evaluate percent changes in volumetric breast density ( $\Delta$ Vbd%) before and after NCT measured automatically and determine its value as a predictive marker of pathological response to NCT.

**Materials and Methods:** A total of 357 patients with breast cancer treated between January 2014 and December 2016 were included. An automated volumetric breast density (Vbd) measurement method was used to calculate Vbd on mammography before and after NCT. Patients were divided into three groups according to  $\Delta$ Vbd%, calculated as follows: Vbd (post-NCT – pre-NCT)/pre-NCT Vbd  $\times$  100 (%). The stable, decreased, and increased groups were defined as  $-20\% \leq \Delta$ Vbd%  $\leq 20\%$ ,  $\Delta$ Vbd%  $< -20\%$ , and  $\Delta$ Vbd%  $> 20\%$ , respectively. Pathological complete response (pCR) was considered to be achieved after NCT if there was no evidence of invasive carcinoma in the breast or metastatic tumors in the axillary and regional lymph nodes on surgical pathology. The association between  $\Delta$ Vbd% grouping and pCR was analyzed using univariable and multivariable logistic regression analyses.

**Results:** The interval between the pre-NCT and post-NCT mammograms ranged from 79 to 250 days (median, 170 days). In the multivariable analysis,  $\Delta$ Vbd% grouping (odds ratio for pCR of 0.420 [95% confidence interval, 0.195–0.905;  $P = 0.027$ ] for the decreased group compared with the stable group), N stage at diagnosis, histologic grade, and breast cancer subtype were significantly associated with pCR. This tendency was more evident in the luminal B-like and triple-negative subtypes.

**Conclusion:**  $\Delta$ Vbd% was associated with pCR in breast cancer after NCT, with the decreased group showing a lower rate of pCR than the stable group. Automated measurement of  $\Delta$ Vbd% may help predict the NCT response and prognosis in breast cancer.

**Keywords:** Mammography; Breast density; Breast neoplasm; Neoadjuvant therapy; Biomarkers; Predictive value of tests

## INTRODUCTION

Neoadjuvant chemotherapy (NCT) is now accepted as a valuable treatment option for breast cancer that enables patients with stage 2–3 disease or particular breast cancer subtypes to improve treatment outcomes and quality of life [1].

Pathological responsiveness to NCT can be a prognostic marker for improved survival, and achievement of ypT0 or ypTis and ypN0 is closely linked to better event-free survival and overall survival [2]. Many researchers have attempted to identify clinical, radiological, and pathological factors to accurately predict pathological complete response (pCR)

**Received:** August 27, 2022 **Revised:** February 8, 2023 **Accepted:** March 10, 2023

**Corresponding author:** Seho Park, MD, PhD, Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.

• E-mail: PSH1025@yuhs.ac; and

Min Jung Kim, MD, PhD, Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.

• E-mail: mines@yuhs.ac

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

after NCT. Clinically, several parameters, including age, stage, histologic grade, estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), Ki-67, and molecular subtype, have been determined as predictive factors of pCR in patients with breast cancer receiving NCT [3-5]. However, persistent efforts must be made to identify other effective predictive factors associated with pCR after NCT.

Breast density can be qualitatively or quantitatively estimated using mammography, three-dimensional digital tomosynthesis, breast magnetic resonance imaging, and computed tomography [6,7]. Mammographic density (MD) is a well-known independent risk factor for breast cancer, and the dynamics of MD using sequential data have been regarded as potential biomarkers for prognosis, especially in patients with breast cancer treated with adjuvant tamoxifen [8,9]. However, research on the association between MD and chemotherapy in patients with breast cancer is limited. Previous studies have suggested that NCT or adjuvant chemotherapy could reduce MD, probably as a secondary effect of chemotherapy-induced amenorrhea [10,11]. Regarding the predictive role of MD scored according to the Breast Imaging-Reporting and Data System (BI-RADS) in patients who underwent NCT, a recent report associated a higher MD at pre-NCT that was visually assessed by an experienced specialist in radiology with failure to achieve pCR, with this relationship being more pronounced in premenopausal patients with breast cancer [12]. In clinical practice, mammography is performed twice, before and after the completion of NCT, to evaluate response, and changes in MD also need to be considered. In addition, automated methods are more popular for volumetric breast density (Vbd) measurements because they increase objectivity and reproducibility. The commercially available Volpara (Matakina Technology Ltd) and Quantra (Hologic Inc.) software perform automated measurements of Vbd and grade them similarly to the BI-RADS categories. Of the two, the Quantra software measures the total breast and fibroglandular tissue volumes by physical modeling, after which the percentage Vbd is calculated as a percentage of fibroglandular tissue and total breast volumes [13]. It generates four density categories by rounding off an estimate of the overall breast composition relative to the reference population.

In this study, we calculated the percent changes in volumetric breast density ( $\Delta$ Vbd%) serially measured automatically using the Quantra software.  $\Delta$ Vbd% was cross-tabulated with various clinicopathological characteristics of patients with breast cancer treated with NCT, and its

association with pCR was analyzed to determine the clinical feasibility of  $\Delta$ Vbd% as a predictive marker of pathological responsiveness to NCT.

## MATERIALS AND METHODS

### Patient Enrollment

A total of 684 patients who were treated with NCT and subsequently underwent breast and axillary surgery between January 2014 and December 2016 were retrospectively screened. The entire study population was evaluated for MD before and after NCT. A total of 357 patients were excluded with the following criteria: stage IV at diagnosis, non-epithelial origin tumor, occult breast cancer with node metastasis, simultaneous bilateral breast cancer, age of < 40 years at diagnosis, male breast cancer, past history of contralateral breast cancer surgery, incomplete administration of planned NCT at diagnosis, inability to undergo examinations for MD both prior to or after receiving NCT, or examinations for which the software failed to obtain quantitative values (Fig. 1). Finally, 357 patients were included in the analysis. This study was approved by the Institutional Review Board of Severance Hospital, Seoul,




Fig. 1. Diagram of patient selection. MD = mammographic density

Republic of Korea (No. 4-2019-1109), and the need for written informed consent was waived.


### MD Assessment

Mammograms were obtained using a full-field digital mammography unit (Lorad Selenia; Hologic). Standard mediolateral oblique and craniocaudal views of the bilateral breasts were obtained for all patients at the time of diagnosis (pre-NCT value) and after the completion of NCT (post-NCT value). Vbd was automatically calculated using the Quantra software (version 2.0; Hologic), which provided the volumes of the total breast tissue (Vb, cm<sup>3</sup>), fibroglandular tissue (Vfg, cm<sup>3</sup>), Vbd (%), and quantized density (Qabd). The pre-NCT and post-NCT values of the non-diseased breast were used for analysis. To focus on the changes in volumetric density during NCT,  $\Delta$ Vbd was calculated as post-NCT Vbd minus pre-NCT Vbd.  $\Delta$ Vbd% was calculated using the following formula:  $(\Delta$ Vbd/pre-NCT Vbd) x 100 (%). As the 25 and 75 percentiles of  $\Delta$ Vbd% in our study population were -18.9% and 16.7%, respectively, we used similar but arbitrarily chosen cutoff values for  $\Delta$ Vbd (-20% and 20%) to divide patients into the decreased, stable, and increased groups ( $\Delta$ Vbd% < -20%, -20%  $\leq$   $\Delta$ Vbd%  $\leq$  20%, and  $\Delta$ Vbd% > 20%, respectively) (Fig. 2).

### Clinicopathological Factors

Clinicopathological characteristics were retrospectively collected from electronic medical records. Age, menopausal

status, body mass index (BMI = weight/height<sup>2</sup>) at diagnosis, age at menarche, marital status, number of full-term deliveries, breastfeeding history, oral contraceptive use, hormone replacement therapy history, clinical stage at diagnosis, NCT regimen, histologic type, histologic grade, subtype, postoperative pathology, and type of breast surgery were compiled. The absence of in situ and invasive carcinomas or residual in situ carcinoma alone, without invasive carcinoma in the breast, and no evidence of metastatic tumors in the axillary and regional lymph nodes on surgical pathology were considered to indicate the achievement of pCR after NCT. Tumors with  $\geq$  1% nuclear-stained cells on immunohistochemistry were considered positive for ER or progesterone receptor (PR) expression according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines [14]. HER2 immunostaining was scored from 0 to 3+, and HER2 equivocal cases were performed using an in situ hybridization test following the ASCO/CAP guidelines for HER2 testing [15]. Ki-67 labeling indices were scored by counting the number of positively stained nuclei and expressed as the percentage of total tumor cells. Ki-67 of > 15% was used as the cutoff for high expression. Breast cancer subtypes were categorized into four subgroups: luminal A-like (ER- and/or PR-positive, HER2-negative, and Ki-67 of  $\leq$  15%), luminal B-like (ER- and/or PR-positive, HER2-negative, and Ki-67 of > 15%, or ER- and/or PR-positive and HER2-positive, irrespective of Ki-67), HER2-



**Fig. 2.** Distribution of changes in volumetric breast density ( $\Delta$ Vbd%) before and after neoadjuvant chemotherapy. The decreased, stable, and increased groups are defined as  $\Delta$ Vbd% < -20%, -20%  $\leq$   $\Delta$ Vbd%  $\leq$  20%, and  $\Delta$ Vbd% > 20%, respectively.

positive (ER-negative, PR-negative, and HER2-positive), and triple-negative breast cancer (TNBC; ER-negative, PR-negative, and HER2-negative). In luminal subtypes that did not have Ki-67 results, histologic grade III was considered high proliferation, and histologic grade I or II was considered low proliferation [16].

### Statistical Analysis

Differences in clinicopathological parameters among the  $\Delta$ Vbd% groups were evaluated using the chi-square test, Fisher's exact test, and one-way analysis of variance with Bonferroni correction according to the data types. Univariable and multivariable logistic regression analyses were used to identify variables that were significantly associated with pCR after NCT. Variables that were statistically significant for pCR in the univariable analysis or those considered clinically important albeit statistically insignificant in the univariable analysis were included in the multivariable analysis. All statistical tests were two-sided, and *P*-values of < 0.05 were considered statistically

significant. SPSS version 25.0 (IBM Inc.) was used for all analyses.

## RESULTS

### Mammographic Characteristics

The interval between the pre-NCT and post-NCT mammograms ranged from 79 to 250 days (median, 170 days). Breast and axillary surgery was performed a median of 185 days after pre-NCT mammography and a median of 14 days after post-NCT mammography. The mean Vbd values were  $15.8\% \pm 9.3\%$  (range, 3%–64%) at pre-NCT and  $15.0\% \pm 8.6\%$  (range, 2%–65%) before surgery (paired *t*-test; *P*-value = 0.003). The parameters of the pre- and post-NCT mammograms are presented according to the  $\Delta$ Vbd% in Table 1. At pre-NCT, the decreased  $\Delta$ Vbd% group showed significantly lower Vb and higher Vbd values than the increased group. The Vfg was significantly lower in the increased  $\Delta$ Vbd% group than in the stable group. The decreased  $\Delta$ Vbd% group demonstrated a higher proportion

**Table 1.** Mammographic Characteristics according to the  $\Delta$ Vbd% Grouping

	All (n = 357)	Decreased $\Delta$ Vbd% (n = 80)	Stable $\Delta$ Vbd% (n = 205)	Increased $\Delta$ Vbd% (n = 72)	<i>P</i> *
<b>Pre-NCT</b>					
Vb, cm <sup>3</sup>	615.7 ± 326.3	530.5 ± 283.4	629.3 ± 317.0	671.5 ± 379.3	0.019
Vfg, cm <sup>3</sup>	87.8 ± 61.8	90.9 ± 72.7	95.6 ± 62.4	61.9 ± 35.2	< 0.001
Vbd, %	15.8 ± 9.3	19.0 ± 10.3	16.4 ± 8.9	10.5 ± 6.4	< 0.001
Qabd <sup>†</sup>					< 0.001 <sup>†</sup>
Q1	31 (8.7)	4 (5.0)	15 (7.3)	12 (16.7)	
Q2	129 (36.1)	21 (26.3)	68 (33.2)	40 (55.6)	
Q3	152 (42.6)	42 (52.5)	92 (44.9)	18 (25.0)	
Q4	45 (12.6)	13 (16.3)	30 (14.6)	2 (2.8)	
<b>Post-NCT</b>					
Vb, cm <sup>3</sup>	589.3 ± 325.4	534.6 ± 271.1	595.8 ± 296.8	631.2 ± 436.8	0.171
Vfg, cm <sup>3</sup>	80.7 ± 54.6	65.8 ± 54.5	86.6 ± 54.7	80.6 ± 51.7	0.015
Vbd, %	15.0 ± 8.6	12.5 ± 6.5	15.9 ± 8.7	15.0 ± 9.9	0.010
Qabd <sup>†</sup>					0.216 <sup>†</sup>
Q1	18 (5.0)	6 (7.5)	9 (4.4)	3 (4.2)	
Q2	152 (42.6)	39 (48.8)	77 (37.6)	36 (50.0)	
Q3	147 (41.2)	30 (37.5)	91 (44.4)	26 (36.1)	
Q4	40 (11.2)	5 (6.3)	28 (13.7)	7 (9.7)	
<b>Between pre-NCT and post-NCT</b>					
$\Delta$ Vbd	-0.8 ± 5.2	-6.5 ± 6.2	-0.5 ± 2.0	4.6 ± 4.0	< 0.001
$\Delta$ Vbd%	0.5 ± 30.0	-32.9 ± 13.5	-2.1 ± 11.6	44.9 ± 25.0	< 0.001

Values are presented as mean ± standard deviation or patient number (%).  $\Delta$ Vbd was calculated as post-NCT Vbd minus pre-NCT Vbd.  $\Delta$ Vbd% was calculated with the following formula:  $(\Delta$ Vbd/pre-NCT Vbd) × 100. The decreased group was defined with  $\Delta$ Vbd% < -20%, the stable group with  $-20\% \leq \Delta$ Vbd% ≤ 20%, and the increased group with  $\Delta$ Vbd% > 20%. \*Analysis of variance (ANOVA) test, <sup>†</sup>Chi-square test, <sup>‡</sup>The number of patients (%). Vb = total breast volume, Vfg = fibroglandular tissue volume, Vbd = volumetric breast density, Qabd = quantized density, NCT = neoadjuvant chemotherapy

of dense Q3 and Q4 in the Qabd. After NCT, the Vb and Qabd did not differ among the three  $\Delta$ Vbd% groups. The decreased  $\Delta$ Vbd% group showed significantly lower Vfg and Vbd values than the stable group. The mean  $\Delta$ Vbd% values were -32.9%, -2.1%, and 44.9% for the decreased, stable, and increased groups, respectively.

### Clinicopathological Characteristics

The median age at diagnosis was 52 (range, 40–79) years for the total study population. The NCT regimens consisted of anthracycline- or taxane-based agents in 12 (3.4%) patients, anthracycline plus cyclophosphamide followed by taxane in 243 (68.1%) patients, anthracycline plus cyclophosphamide followed by taxane plus targeted agents in 76 (21.3%) patients, and taxane-based agents plus targeted agents in 26 (7.3%) patients.

The clinicopathological characteristics are summarized in Table 2. The decreased  $\Delta$ Vbd% group included younger age, premenopausal women, no history of full-term delivery, and larger tumor size. This group was significantly less likely to achieve pCR after NCT. There were no differences in BMI, age at menarche, marital status, breastfeeding history, oral contraceptive use, hormone replacement therapy use, nodal status, NCT regimen, histologic type, histologic grade, or breast cancer subtype. Patients with a decreased  $\Delta$ Vbd% were more likely to undergo total mastectomy with borderline statistical significance.

### Analyses of the Association with pCR

After NCT, breast pCR, irrespective of nodal status, was achieved in 137 (38.4%) patients. Eighty-nine patients did not have residual invasive and in situ carcinomas, whereas 48 patients only had residual in situ disease. Axillary pCR, irrespective of the primary tumor status, was detected in 225 (63.0%) patients. Overall, tumor and nodal pCR after NCT were achieved in 128 (35.9%) patients. Images of pCR and non-pCR associated with breast density assessment using Quantra are shown in Figures 3 and 4.

The predictive factors that were significantly associated with pCR after NCT are shown in Table 3. In the univariable logistic regression analysis, the decreased  $\Delta$ Vbd% group had a significantly lower probability of pCR than the stable group. These findings were noticeable in premenopausal patients; the pCR rates were 18.5% in 54 premenopausal women with decreased  $\Delta$ Vbd% and 26.9% in 26 postmenopausal patients with decreased  $\Delta$ Vbd%. When the pre-NCT and post-NCT Qabd values were analyzed, pre-

**Table 2.** Clinicopathological Characteristics according to the  $\Delta$ Vbd% Grouping

	Decreased $\Delta$ Vbd%	Stable $\Delta$ Vbd%	Increased $\Delta$ Vbd%	P
Age at diagnosis, yr				< 0.001*
Mean $\pm$ standard deviation	49.2 $\pm$ 7.0	52.5 $\pm$ 7.6	56.4 $\pm$ 8.3	
Menopausal status				< 0.001
Premenopause	54 (67.5)	91 (44.4)	17 (23.6)	
Postmenopause	26 (32.5)	114 (55.6)	55 (76.4)	
BMI, kg/m <sup>2</sup>				0.689
< 23	38 (47.5)	101 (49.3)	31 (43.1)	
23– < 27	31 (38.8)	75 (36.6)	26 (36.1)	
$\geq$ 27	11 (13.8)	29 (14.1)	15 (20.8)	
Age at menarche, yr				0.230
$\leq$ 13	25 (31.3)	43 (21.0)	11 (15.3)	
14–15	32 (40.0)	88 (42.9)	30 (41.7)	
$\geq$ 16	18 (22.5)	65 (31.7)	27 (37.5)	
Unknown	5 (6.3)	9 (4.4)	4 (5.6)	
Marital status				0.711 <sup>†</sup>
Unmarried	6 (7.5)	12 (5.9)	3 (4.2)	
Married/divorced	74 (92.5)	193 (94.1)	69 (95.8)	
No. of full-term deliveries				0.025
0 child	12 (15.0)	15 (7.3)	4 (5.6)	
1 child	15 (18.8)	36 (17.6)	19 (26.4)	
2 children	36 (45.0)	127 (62.0)	34 (47.2)	
$\geq$ 3 children	17 (21.3)	27 (13.2)	15 (20.8)	
Breast feeding history				0.308 <sup>†</sup>
No	24 (30.0)	59 (28.8)	14 (19.4)	
Yes	54 (67.5)	135 (65.9)	52 (72.2)	
Unknown	2 (2.5)	11 (5.4)	6 (8.3)	
Oral contraceptives use				0.932 <sup>†</sup>
No	64 (80.0)	167 (81.5)	57 (79.2)	
Yes	16 (20.0)	36 (17.6)	15 (20.8)	
Unknown	0 (0.0)	2 (1.0)	0 (0.0)	
HRT history				0.137 <sup>†</sup>
No	75 (93.8)	182 (88.8)	59 (81.9)	
Yes	5 (6.3)	21 (10.2)	13 (18.1)	
Unknown	0 (0.0)	2 (1.0)	0 (0.0)	
T stage at diagnosis				0.048
cT1	10 (12.5)	23 (11.2)	10 (13.9)	
cT2	41 (51.2)	136 (66.3)	50 (69.4)	
cT3–4	29 (36.3)	46 (22.4)	12 (16.7)	
N stage at diagnosis				0.892
cN0	15 (18.8)	47 (22.9)	14 (19.4)	
cN1	46 (57.5)	115 (56.1)	40 (55.6)	
cN2–3	19 (23.8)	43 (21.0)	18 (25.0)	
NCT regimen				0.331
A or Taxane-based alone	5 (6.3)	5 (2.4)	2 (2.8)	

**Table 2.** Clinicopathological Characteristics according to the  $\Delta$ Vbd% Grouping (continued)

	Decreased $\Delta$ Vbd%	Stable $\Delta$ Vbd%	Increased $\Delta$ Vbd%	<i>P</i>
A → Taxane	60 (75.0)	135 (65.9)	48 (66.7)	
A → Taxane + anti-HER2 agent	11 (13.8)	49 (23.9)	16 (22.2)	
Taxane + anti-HER2 agent	4 (5.0)	16 (7.8)	6 (8.3)	
Histology type				0.878 <sup>†</sup>
Ductal	73 (91.3)	188 (91.7)	67 (93.1)	
Lobular	2 (2.5)	7 (3.4)	3 (4.2)	
Others	5 (6.3)	10 (4.9)	2 (2.8)	
Histologic grade				0.321
I	14 (17.5)	24 (11.7)	6 (8.3)	
II	50 (62.5)	124 (60.5)	49 (68.1)	
III	16 (20.0)	57 (27.8)	17 (23.6)	
Breast cancer subtype				0.089
Luminal A-like	30 (37.5)	60 (29.3)	19 (26.4)	
Luminal B-like	22 (27.5)	44 (21.5)	11 (15.3)	
HER2-positive	8 (10.0)	44 (21.5)	15 (20.8)	
TNBC	20 (25.0)	57 (27.8)	27 (37.5)	
Postoperative pathology				0.008
pCR	17 (21.3)	82 (40.0)	29 (40.3)	
Non-pCR	63 (78.8)	123 (60.0)	43 (59.7)	
Type of breast surgery				0.058
BCS	39 (48.8)	107 (52.2)	48 (66.7)	
Total mastectomy	41 (51.2)	98 (47.8)	24 (33.3)	

Data are number of patients (%), unless specified otherwise.

\*Analysis of variance (ANOVA) test, <sup>†</sup>Fisher's exact test. BMI = body mass index, No. = number, HRT = hormone replacement therapy, NCT = neoadjuvant chemotherapy, A = anthracycline, HER2 = human epidermal growth factor receptor 2, TNBC = triple-negative breast cancer, pCR = pathological complete response, BCS = breast conservation surgery, Vbd = volumetric breast density

NCT Q4 alone was associated with a significantly lower probability of pCR (odds ratio, 0.305; 95% confidence interval, 0.113–0.824; *P*-value = 0.019). However, post-NCT Q2, Q3, and Q4 were less likely to achieve pCR (Table 3); therefore, the post-NCT Qabd was selected for the multivariable model because the pre-NCT Qabd was closely related to the post-NCT Qabd. Menopausal status, clinical node stage at diagnosis, NCT regimen, histologic grade, and breast cancer subtype were also statistically associated with pCR. The remaining clinical variables were not associated with pCR (data not shown).

In the multivariable analysis, the breast cancer subtype was the most powerful predictor of pCR. Node staging at diagnosis, histologic grade III, and a combination of anti-HER2 agents were also significantly associated with

pCR. Vbd measurements were statistically significant. Patients with preoperatively dense breast Q3 and Q4 after completion of NCT were less likely to achieve pCR, and the decreased  $\Delta$ Vbd% group also had a lower probability of pCR after NCT independently.

When a subgroup analysis stratified by breast cancer subtype was performed (Table 4), the decreased  $\Delta$ Vbd% group had significantly lower pCR rates in patients with the luminal B-like and TNBC subtypes. Changes in the Vbd were not related to pCR achievement in luminal A-like and HER2-positive breast cancers.


## DISCUSSION

In the early 2000s, quantitative methods were developed, and automated volume measurement was implemented to overcome the subjectivity of radiology specialists, to compensate for the difference in X-ray exposure according to the degree of mammography pressure, and in response to the need for three-dimensional area measurements for breast density [17].

In this study, we objectively measured the MD using automated density assessments. We focused on the individual effects of chemotherapy on breast density during a relatively short treatment course and calculated the changes in the Vbd before and after NCT. We eventually revealed that a decrease in the Vbd difference that grew larger after NCT was a poor predictive factor of pCR, especially in patients with luminal B-like breast cancer and TNBC.

According to Skarping et al. [18], three-quarters of patients who received NCT prospectively showed that the post-NCT MD was lower than the pre-NCT MD. Patients with pCR did not show significant changes in the volumetric MD between pre- and post-NCT examinations despite adjustment for other clinicopathological variables. However, half of the patients in our cohort showing decreased absolute Vbd values after NCT were young and premenopausal and had dense breasts at diagnosis compared with the other patients. Importantly, patients with decreased  $\Delta$ Vbd% were less likely to achieve pCR on multivariable analysis, suggesting that the degree of change in the volumetric MD was a valuable predictive factor of chemotherapeutic effects, namely, the achievement of pCR. In addition, this association was more pronounced in luminal B-like breast cancer and TNBC than in luminal A-like or HER2-positive breast cancers.

Both adjuvant tamoxifen and NCT were associated



**Fig. 3.** A case of pathological complete response (pCR) associated with breast density assessment using Quantra. The pre-neoadjuvant chemotherapy (A) and post-neoadjuvant chemotherapy (B) images of a patient with increased percent changes in volumetric breast density ( $\Delta$ Vbd%) of left breast and pCR of right breast are shown. The Vbd (%) increases from 6 to 13.


with reduced MD in the treatment of ER-positive breast cancer. Several studies have shown improved prognosis in 30%–60% of patients treated with adjuvant tamoxifen who also showed reduced MD [19,20]. Kim et al. [21] reported that in patients who had MD that decreased to < 5% or increased after 1 year of adjuvant endocrine therapy, the risk of recurrence approximately doubled or was greater than in those who had MD that decreased to > 10%. They also suggested that a decrease in circulating estrogen due to adjuvant endocrine therapy could lead to a decrease in MD; however, this has not yet been proven.

Aktepe et al. [22] showed that NCT can induce lobular atrophy and alter the composition of dense breast parenchymal regions forming MD to fibrosis and hyalinization. These studies have shown that MD or Vbd decreases after NCT and is associated with higher MD at

diagnosis with a lower pCR rate [10,23].

Recently, Swedish researchers analyzed the association between pCR after NCT and MD using visual assessment with BI-RADS in 495 patients with breast cancer [12]. In a model adjusted for patient age, BMI, and menopausal status, the pCR rates were significantly lower in premenopausal women classified as BI-RADS D, which represents extremely dense breasts [12]. Consistently, our multivariable analysis confirmed that higher Qabd categories and decreased  $\Delta$ Vbd% were significantly independently associated with lower pCR rates, whereas aggressive breast cancer subtype, high-grade tumor, and use of anti-HER2 agents with chemotherapy were significantly associated with increased pCR rates after NCT.

Currently, there are two commercial programs available for automated Vbd measurements: Quantra and Volpara. Breast



**Fig. 4.** A case of non-pathological complete response (non-pCR) associated with breast density assessment using Quantra. The pre-neoadjuvant chemotherapy (A) and post-neoadjuvant chemotherapy (B) images of a non-pCR patient with decreased percent changes in volumetric breast density ( $\Delta$ Vbd%) of left breast are shown. The Vbd (%) decreases from 14 to 7, and residual cancer is visible.

thickness is measured by accumulating X-rays, and patients undergo additional processes to classify the breast into dense and nondense tissues [24]. In previous publications, the automated density method differed by up to 14% from visual assessment and was associated with a risk measure for developing breast cancer. Differences were also observed in the capabilities of the two automated programs for volumetric density measurements. Youk et al. [25] reported that Quantra is more useful for classifying nondense breast tissue, and Volpara can classify more images of denser breast tissue than visual assessment. Compared with visual evaluation, Quantra and Volpara were correlated with MD ( $\gamma = 0.79-0.99$ ,  $P < 0.001$ ), although the regions studied by the Volpara and Quantra software were reported to be different.

Although pCR-related chemosensitivity is unclear in obese patients receiving NCT, patients with a high BMI ( $\geq 25$  kg/m<sup>2</sup>) and high visceral fat are generally known to show poor prognosis [26,27]. Obesity causes changes that alter the body's physiological environment, making it resistant to insulin, causing sustained chronic inflammation,

and increasing the secretion of endogenous steroids associated with carcinogenesis and cancer progression [28]. Approximately 15% of the patients in our study population were obese; however, a higher BMI was not associated with responsiveness to NCT. Future studies with larger sample sizes should be conducted.

The current study has some limitations. First, we retrospectively ran a single automated volumetric program at one institution to collect data, and the number of study subjects was too small to reflect the entire population. It was also difficult to specifically reflect the differences in each NCT regimen according to the type of breast cancer. More importantly, the degree of  $\Delta$ Vbd% was classified into decreased or increased levels with arbitrary cutoff values, which means that the results need to be interpreted with caution. A larger study that would enable the exploration of different grouping methods and cutoffs or analysis of  $\Delta$ Vbd% as a continuous variable would be needed. Second, changes in body weight during NCT could not be incorporated directly, and dynamic BMI changes could not be

**Table 3.** Univariable and Multivariable Logistic Regression Analysis for the Achievement of Pathological Complete Response after Neoadjuvant Chemotherapy

Variables	Univariable			Multivariable		
	OR	95% CI	P	OR	95% CI	P
<b>ΔVbd%</b>						
Stable	Ref			Ref		
Decreased	0.405	0.221–0.741	0.003	0.420	0.195–0.905	0.027
Increased	1.012	0.585–1.749	0.967	1.043	0.525–2.070	0.905
<b>Post-NCT Qabd</b>						
Q1	Ref			Ref		
Q2	0.284	0.101–0.798	0.017	0.222	0.058–0.854	0.029
Q3	0.235	0.083–0.665	0.006	0.151	0.037–0.618	0.008
Q4	0.269	0.083–0.873	0.029	0.199	0.040–1.002	0.050
<b>Menopausal status</b>						
Premenopause	Ref			Ref		
Postmenopause	1.571	1.011–2.440	0.045	0.903	0.475–1.720	0.757
<b>BMI, kg/m<sup>2</sup></b>						
< 23	Ref			Ref		
23– < 27	0.985	0.617–1.573	0.950	1.154	0.626–2.129	0.646
≥ 27	0.500	0.250–1.002	0.051	0.769	0.316–1.872	0.563
<b>N stage at diagnosis</b>						
cN0	Ref			Ref		
cN1	0.314	0.181–0.543	< 0.001	0.345	0.170–0.700	0.003
cN2-3	0.599	0.318–1.130	0.113	0.408	0.185–0.898	0.026
<b>NCT regimen</b>						
A, Taxane or combined	Ref			Ref		
A → Taxane + anti-HER2 agent	3.265	1.923–5.542	< 0.001	3.557	1.250–10.123	0.017
Taxane + anti-HER2 agent	4.229	1.832–9.762	0.001	3.157	0.858–11.616	0.084
<b>Histologic grade</b>						
I/II	Ref			Ref		
III	6.744	3.986–11.409	< 0.001	3.986	2.065–7.696	< 0.001
<b>Breast cancer subtype</b>						
Luminal A-like	Ref			Ref		
Luminal B-like	7.774	2.994–20.180	< 0.001	2.742	0.838–8.971	0.095
HER2-positive	30.757	11.744–80.551	< 0.001	7.150	1.715–29.800	0.007
TNBC	19.269	7.776–47.809	< 0.001	6.533	2.327–18.340	< 0.001
<b>ΔVbd% × Breast cancer subtype</b>						
Decreased × Luminal B-like				0.199	0.045–0.871	0.032
Decreased × HER2-positive				5.965	1.179–30.182	0.031
Decreased × TNBC				0.852	0.316–2.296	0.752
Increased × Luminal B-like				1.136	0.324–3.989	0.842
Increased × HER2-positive				1.740	0.610–4.958	0.300
Increased × TNBC				3.976	1.714–9.225	0.001

OR = odds ratio, CI = confidence interval, Vbd = volumetric breast density, NCT = neoadjuvant chemotherapy, Qabd = quantized density, BMI = body mass index, Ref = reference category, A = anthracycline, HER2 = human epidermal growth factor receptor 2, TNBC = triple-negative breast cancer

adjusted for the analysis. Third, even if the same inspectors perform examinations on the same patient using the same equipment at a single institution, imaging parameters may differ between examinations because the machine runs

automatically with settings decided by the patient's present condition. NCT can change the tumor status of the breast, and such changes may be more pronounced in patients with pCR. Finally, patients who could not be assessed for MD were

**Table 4.** Association between  $\Delta$ Vbd% and pCR Stratified by Breast Cancer Subtype

	Decreased $\Delta$ Vbd%	Stable $\Delta$ Vbd%	Increased $\Delta$ Vbd%	<i>P</i>
Luminal A-like				0.451
pCR	3 (10.0)	3 (5.0)	0 (0.0)	
Non-pCR	27 (90.0)	57 (95.0)	19 (100)	
Luminal B-like				0.030
pCR	2 (9.1)	18 (40.9)	4 (36.4)	
Non-pCR	20 (90.9)	26 (59.1)	7 (63.6)	
HER2-positive				0.282
pCR	6 (75.0)	30 (68.2)	7 (46.7)	
Non-pCR	2 (25.0)	14 (31.8)	8 (53.3)	
TNBC				0.042
pCR	6 (30.0)	31 (54.4)	18 (66.7)	
Non-pCR	14 (70.0)	26 (45.6)	9 (33.3)	

Data are number of patients (%). Vbd = volumetric breast density, pCR = pathological complete response, HER2 = human epidermal growth factor receptor 2, TNBC = triple-negative breast cancer

excluded from this analysis, and the potential for selection bias remained.

In conclusion, chemotherapy with or without anti-HER2 therapy decreased the breast density, and  $\Delta$ Vbd% was associated with the likelihood of achieving pCR after NCT in patients with breast cancer. A decreased  $\Delta$ Vbd% after NCT may be an unfavorable factor for pCR, especially for the luminal B-like or TNBC subtypes. Automated measurement of  $\Delta$ Vbd% can be considered when predicting treatment response to NCT and cancer prognosis. A larger study is required to validate our results.

#### Availability of Data and Material

The datasets generated or analyzed during the study are not publicly available due their containing information that could compromise the privacy of research participants but are available from the corresponding author on reasonable request.

#### Conflicts of Interest

Min Jung Kim, a contributing editor of the *Korean Journal of Radiology*, was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.

#### Author Contributions

Conceptualization: Min Jung Kim, Seho Park. Data curation: Seho Park, Jee Hyun Ahn. Formal analysis: Seho Park, Jee Hyun Ahn. Funding acquisition: Min Jung Kim. Investigation: Seho Park, Jee Hyun Ahn, Jieon Go, Suk

Jun Lee. Methodology: Seho Park, Min Jung Kim. Project administration: Seho Park, Min Jung Kim. Resources: Byeong-Woo Park, Seung Il Kim, Seho Park, Hyung Seok Park, Jee Ye Kim, Min Jung Kim, Jung Hyun Yoon, Vivian Youngjean Park. Software: Seho Park, Jee Hyun Ahn. Supervision: Seho Park, Min Jung Kim. Validation: Seho Park, Jee Hyun Ahn. Visualization: Seho Park, Jee Hyun Ahn. Writing—original draft: Seho Park, Jee Hyun Ahn. Writing—review & editing: Min Jung Kim, Seho Park, Jee Hyun Ahn.

#### ORCID iDs

Jee Hyun Ahn

<https://orcid.org/0000-0003-4176-3277>

Jieon Go

<https://orcid.org/0000-0002-4827-0929>

Suk Jun Lee

<https://orcid.org/0000-0003-3839-5071>

Jee Ye Kim

<https://orcid.org/0000-0003-3936-4410>

Hyung Seok Park

<https://orcid.org/0000-0001-5322-6036>

Seung Il Kim

<https://orcid.org/0000-0001-9673-2748>

Byeong-Woo Park

<https://orcid.org/0000-0003-1353-2607>

Vivian Youngjean Park

<https://orcid.org/0000-0002-5135-4058>

Jung Hyun Yoon

<https://orcid.org/0000-0002-2100-3513>

Min Jung Kim

<https://orcid.org/0000-0003-4949-1237>

Seho Park

<https://orcid.org/0000-0001-8089-2755>

#### Funding Statement

This study was supported by a faculty research grant of Yonsei University College of Medicine (6-2019-0168). This work was also supported by the Korea Medical Device Development Fund grant funded by the Korean government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, Republic of Korea, the Ministry of Food and Drug Safety) (Project Number: KMDF202011A01-04) and MSIT (NRF-2021R1A2C3006264). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## REFERENCES

1. Burstein HJ, Curigliano G, Loibl S, Dubsy P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. *Ann Oncol* 2019;30:1541-1557
2. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* 2014;384:164-172
3. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. *Ann Surg Oncol* 2012;19:1508-1516
4. Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fifth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2013). *J Natl Cancer Inst Monogr* 2015;2015:90-96
5. Rubovszky G, Horváth Z. Recent advances in the neoadjuvant treatment of breast cancer. *J Breast Cancer* 2017;20:119-131
6. Chen JH, Gulsen G, Su MY. Imaging breast density: established and emerging modalities. *Transl Oncol* 2015;8:435-445
7. Vinnicombe SJ. Breast density: why all the fuss? *Clin Radiol* 2018;73:334-357
8. Andersson TM, Crowther MJ, Czene K, Hall P, Humphreys K. Mammographic density reduction as a prognostic marker for postmenopausal breast cancer: results using a joint longitudinal-survival modeling approach. *Am J Epidemiol* 2017;186:1065-1073
9. Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, et al. Body size, mammographic density, and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2006;15:2086-2092
10. Jang HJ, Kim HJ, Chae YS, Lee SJ, Kim SH, Lee H, et al. Effect of neoadjuvant chemotherapy on breast tissue composition: a longitudinal mammographic study with automated volumetric measurement. *Eur Radiol* 2020;30:4785-4794
11. Eriksson L, He W, Eriksson M, Humphreys K, Bergh J, Hall P, et al. Adjuvant therapy and mammographic density changes in women with breast cancer. *JNCI Cancer Spectr* 2018;2:pk071
12. Skarping I, Förnvik D, Heide-Jørgensen U, Sartor H, Hall P, Zackrisson S, et al. Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients. *Cancer Causes Control* 2021;32:251-260
13. Ekpo EU, McEntee MF. Measurement of breast density with digital breast tomosynthesis--a systematic review. *Br J Radiol* 2014;87:20140460
14. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol* 2010;28:2784-2795
15. Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M. HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update summary. *J Oncol Pract* 2018;14:437-441
16. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. *Breast Cancer Res Treat* 2011;127:591-599
17. Jeffreys M, Warren R, Highnam R, Smith GD. Initial experiences of using an automated volumetric measure of breast density: the standard mammogram form. *Br J Radiol* 2006;79:378-382
18. Skarping I, Förnvik D, Heide-Jørgensen U, Sartor H, Hall P, Zackrisson S, et al. Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden. *Breast* 2020;53:33-41
19. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. *J Natl Cancer Inst* 2004;96:621-628
20. Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, et al. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. *J Natl Cancer Inst* 2015;107:dju425
21. Kim J, Han W, Moon HG, Ahn S, Shin HC, You JM, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. *Breast Cancer Res* 2012;14:R102
22. Aktepe F, Kapucuoğlu N, Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. *Histopathology* 1996;29:63-67
23. Skarping I, Förnvik D, Sartor H, Heide-Jørgensen U, Zackrisson S, Borgquist S. Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer. *BMC Cancer* 2019;19:1272
24. Brandt KR, Scott CG, Ma L, Mahmoudzadeh AP, Jensen MR, Whaley DH, et al. Comparison of clinical and automated breast density measurements: implications for risk prediction and supplemental screening. *Radiology* 2016;279:710-719
25. Youk JH, Gweon HM, Son EJ, Kim JA. Automated volumetric breast density measurements in the era of the BI-RADS fifth edition: a comparison with visual assessment. *AJR Am J Roentgenol* 2016;206:1056-1062
26. Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. *Breast Cancer Res Treat* 2015;150:127-139
27. Iwase T, Sangai T, Nagashima T, Sakakibara M, Sakakibara J, Hayama S, et al. Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. *Cancer Med* 2016;5:41-48
28. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. *Cancer Epidemiol Biomarkers Prev* 2009;18:2569-2578